A new COO and a bigger footprint

Cromos looks to establish a more global presence

Register for free to listen to this article
Listen with Speechify
PORTLAND, Ore.—Toward the end of 2017, Cromos Pharma, a regional contract research organization (CRO), announced that Stephanie Finnegan had been appointed as its chief operating officer—she joined the company’s U.S. office and will oversee its European and U.S. operations.
“We are very excited to see Ms. Finnegan joining our team,” said Dr. Vlad Bogin, Cromos Pharma’s CEO. “She brings decades of clinical research and business development experience and her addition marks a quantitative change in the company’s development. We plan to utilize Stephanie’s knowledge of U.S. and international clinical operations to further Cromos Pharma’s reputation of a fully integrated CRO capable of providing a full spectrum of services to biotech and pharma companies of all sizes.”
“Joining Cromos Pharma was an easy decision for me,” Finnegan said. “I was looking for an opportunity to do what I enjoy most—to work with a young and growing company looking to establish a global presence. After meeting with Dr. Bogin and the leadership team at Cromos, I knew that this was the right fit. The team is talented, eager and dedicated to unimpeachable quality and client service. There is limitless potential here, and I am honored to become a member of the Cromos family.”
Finnegan has nearly three decades of experience in the biopharmaceutical industry. Prior to joining Cromos Pharma, she was the president of a U.S.-based CRO that operated predominantly in Eastern Europe and helped to lead that CRO into the global market and establish a dominant position in biologics and biosimilars. Prior to joining that CRO, she founded and led the biopharmaceutical industry’s first contract manufacturer dedicated to the clinical development of biotherapeutics.
Cromos Pharma is a U.S.-based CRO with a strong operational presence in the post-Soviet space and in Eastern/Central Europe. The company provides a full spectrum of trial-related services which include clinical monitoring, regulatory approvals, medical writing, feasibility assessments, project management and warehousing.

Published In:

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue